Classic Hodgkin lymphoma is the most common cancer among teenagers. And despite the high cure rate with first-line and salvage therapy, 15 to 20% of patients do not achieve a long-term disease-free survival. So, we need new alternative therapies in this setting and CAR-T cell therapy could be a promising approach.
We decided to develop a new target strategy by anti-CD30 CAR-T cell, coupled with a PD-L1 costimulatory receptor to overcome the resistance of the tumor microenvironment...
Classic Hodgkin lymphoma is the most common cancer among teenagers. And despite the high cure rate with first-line and salvage therapy, 15 to 20% of patients do not achieve a long-term disease-free survival. So, we need new alternative therapies in this setting and CAR-T cell therapy could be a promising approach.
We decided to develop a new target strategy by anti-CD30 CAR-T cell, coupled with a PD-L1 costimulatory receptor to overcome the resistance of the tumor microenvironment. CD30 CAR-T cells have been explored by several CAR constructs, but despite the initial overall response rate, most of these CAR-T cells do not persist in time.
The longer follow-up of these trials showed that the progression-free survival is quite low. So we need to boost the T-cell activation on the tumor microenvironment to let persist CAR-T cells more time in the tumor microenvironment to achieve a more deep response.